Document is current

Any future updates will be listed below

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes

Crossref DOI link: https://doi.org/10.1007/s12020-015-0688-5

Published Online: 2015-07-25

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark